Synmedix is a newly-founded biotechnology company created to commercialize a novel platform that dramatically enhances the effectiveness of antibiotics to address unmet medical need posed by the global health crisis in antibiotic resistance. Synmedix was founded on McMaster University technology, showing that bicarbonate dramatically improves the efficacy and spectrum of several antibiotics enabling the treatment of multidrug-resistant infections.
Synmedix is developing new antibiotic therapies for treating critical infections. Antibiotic resistance is one of the biggest threats to human health, and has undermined a linchpin of modern healthcare we depend on. Our mission is to deliver new therapies that avoid the pitfalls of the past – avoiding resistance, addressing clinical gaps, and delivering solid economics in an equitable manner. Our lead product is a first-in-class therapy developed to treat infections in patients suffering from diabetic foot ulcers.